Deflazacort in Duchenne muscular dystrophy: A comparison of two different protocols

Neuromuscular Disorders

Volumn 14, Issue 8-9, 2004, Pages 476-482

  Biggar, W D ^a,c   Politano, L ^b   Harris, V A ^a   Passamano, L ^b   Vajsar, J ^a   Alman, B ^a   Palladino, A ^b   Comi, L I ^b   Nigro, G ^b,c  

^a HOLLAND BLOORVIEW KIDS REHABILITATION HOSPITAL   (Canada)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c Italy ^*  (Italy)

Author keywords

Deflazacort; Duchenne Muscular Dystrophy; Treatment protocols

Indexed keywords

CALCIUM; DEFLAZACORT; VITAMIN D;

ADOLESCENT; BRACE; CATARACT; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DUCHENNE MUSCULAR DYSTROPHY; ECCHYMOSIS; FRACTURE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INFECTION; MALE; MOBILIZATION; MUSCLE BIOPSY; MUSCLE WEAKNESS; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; SCHOOL CHILD; SCOLIOSIS;

EID: 4344702443     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmd.2004.05.001     Document Type: Article

References (45)

1. McDonald C.M., Abresch R.T., Carter G.T., et al. Profiles of neuromuscular diseases: Duchenne muscular dystrophy. Am J Phys Med Rehabil. 74:(suppl 5):1995;S50-S92
2. Brooke M.H., Fenichel G.M., Griggs R.C., et al. Clinical investigation in Duchenne dystrophy. 2. Determination of the power of therapeutic trials based on the natural history. Muscle Nerve. 6:1983;91-103
3. Emery A.E.H. Duchenne muscular dystrophy. 2nd ed.:1993;Oxford University Press, Oxford
4. Dubowitz V. Muscle disorders in childhood. 1995;Saunders, London. p. 325-69
5. Angelini C., Micaglio G.F., Trevisan C., et al. Natural history of muscular dystrophy inferred from a multicenter trial and the results of a dietetic trial. Minerva Pediatr. 38:(15/16):1986;645-649
6. Rideau Y., Jankowski L.W., Grellet J. Respiratory function in the muscular dystrophies. Muscle Nerve. 4:1981;155-164
7. Griggs R.C., Donohoe K.M., Utell M.J., Goldblatt D., Moxley R.T. Evaluation of pulmonary function in neuromuscular disease. Arch Neurol. 38:1981;9-12
8. Polgar G., Prohadhar V. Pulmonary function testing in children. Tech Stand. 1971;W.B. Saunders, Philadelphia
9. Hahn A., Bach J.R., Deblaubier A., Renardel-Irani A., Guillou C., Rideau Y. Clinical implications of maximal respiratory pressure determinations for individuals with Duchenne muscular dystrophy. Arch Phys Med Rehabil. 78:1997;1-6
10. Baydur A., Gilgoff I., Prentice W., Carlson M., Fischer D.A. Decline in respiratory function and experience with long-term assisted ventilation in advanced Duchenne's muscular dystrophy. Chest. 97:1990;884-889
11. Nigro G., Comi L.I., Politano L., Bain R.J.I. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol. 26:1990;271-277
12. Nigro G., Muntoni F. Forty-second ENMC Sponsored International Workshop: X-linked cardiomyopathies. Neuromusc Disord. 7:1997;397-403
13. Nigro G., Comi L.I., Politano L., Nigro G. Cardiomyopathies associated with muscular dystrophies. A Engel-C Franzini-Armstrong ed. Myology. 2004;McGraw-Hill, New York. [in press]
14. Hodgetts S.I., Grounds M.D. Irradiation of dystrophic host tissue prior to myoblast transfer therapy enhances initial (but not long-term) survival of donor myoblasts. J Cell Sci. 116:2003;4131-4146
15. Sampaolesi M., Torrente Y., Innocenzi A., et al. Cell therapy of alpha-sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts. Science. 301:2003;487-492
16. Lu Q.L., Mann C.J., Lou F., et al. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat Med. 9:2003;1009-1014
17. Drachman D.B., Toyka K.V., Myer E. Prednisone in muscular dystrophy. Lancet. 2:1974;1409-1412
18. DeSilva S., Drachman D.B., Mellits D., Kuncl B.W. Prednisone treatment in Duchenne muscular dystrophy. Long-term benefit. Arch Neurol. 44:1987;818-822
19. Mendell J.R., Moxley R.T., Griggs R.C., et al. Randomized, double blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med. 320:1989;1592-1597
20. Oexle K. Prednisone therapy for Duchenne's muscular dystrophy. N Engl J Med. 321:1989;1481-1482
21. Fenichel G.M., Florence J.M., Pestronk A., et al. Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology. 41:1991;1874-1877
22. Brooke M.H., Fenichel G.M., Griggs R.C., et al. Clinical investigation of Duchenne muscular dystrophy: interesting results in a trial of prednisone. Arch Neurol. 44:1987;812-817
23. Griggs R.C., Moxley R.T., Mendell J.R., et al. Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology. 43:1993;520-526
24. Moxley R.T., Lorenson M., Griggs R.C., et al. Decreased breakdown of muscle protein after prednisone therapy in Duchenne dystrophy (DD). J Neurol Sci. 98:1990;419
25. Markham A., Bryson H.M. Deflazacort. A review of its pharmacological properties and therapeutic efficacy. Drugs. 50:(2):1995;317-333
26. Reitter B. Deflazacort vs. prednisone in Duchenne muscular dystrophy: trends of an ongoing study. Brain Dev. 17:1995;39-43
27. Reitter B. DMD meeting. Neuromusc Disord. 8:1998;216
28. Mesa L.E., Dubrovsky A.L., Corderi J., Marco P., Flores D. Steroids in Duchenne muscular dystrophy - deflazacort trial. Neuromusc Disord. 1:(4):1991;261-266
29. Angelini C., Pegoraro E., Turella E., Intino M.T., Pini A., Costa C. Deflazacort in Duchenne dystrophy: study of long-term effect. Muscle Nerve. 17:1994;386-391
30. Dubrovsky A.L., De Vito E., Suarez A., et al. Deflazacort treatment and respiratory function in Duchenne muscular dystrophy. Neurology. 52A:(suppl 2):1999;544
31. Biggar W.D., Gingras M., Fehlings D.L., Harris V.A., Steele C.A. Deflazacort treatment of Duchenne muscular dystrophy. J Pediatr. 138:2001;45-50
32. Silversides C.K., Webb G.D., Harris V.A., Biggar W.D. Effects of Deflazacort on left ventricular function in patients with Duchenne muscular dystrophy. Am J Cardiol. 91:2003;769-772
33. Alman B.A., Raza S.N., Biggar W.D. Steroid treatment and the development of scoliosis in males with Duchenne muscular dystrophy. J Bone Joint Surg. 86A:(3):2004;519-524
34. SAS Institute Inc. SAS/STAT User's Guide, version 6. 4th ed.:1994;SAS Institute Inc, Cary, NC
35. Fenichel G.M., Mendall J.R., Moxley R.T., et al. A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy. Arch Neurol. 48:1991;475-479
36. Weimann R.L., Gibson D.A., Mosley C.V., Jones D.C. Surgical stabilization of the spine in Duchenne muscular dystrophy. Spine. 8:(7):1983;776-780
37. Jaffe K.M., McDonald C.M., Ingman E., Haas J. Symptoms of upper gastrointestinal dysfunction in Duchenne muscular dystrophy: case-control study. Arch Phys Med Rehabil. 71:1990;742-744
38. Willig T.N., Carlier L., Legrand M., Rivière H., Navarro J. Nutritional assessment in Duchenne muscular dystrophy. Dev Med Child Neurol. 35:1993;1074-1082
39. McCrory M.A., Wright N.C., Kilmer D.D. Nutritional aspects of neuromuscular diseases. Rehabil Neuromusc Dis. 9:1998;127-143
40. Zata B.M., Betti R.T. RTB benign Duchenne muscular dystrophy in a patient with growth hormone deficiency: a five year follow-up. Am J Genet. 24:1986;567-572
41. McDonald D.G.M., Kinali M., Gallagher A.G., et al. Fracture prevalence in Duchenne muscular dystrophy. Dev Med Child Neurol. 44:2002;695-698
42. Larson C.M., Henderson R.C. Bone mineral density and fractures in boys with Duchenne muscular dystrophy. J Pediatr Orthop. 20:2000;71-74
43. Bothwell J.E., Gordon K.E., Dooley J.M., MacSween J., Cummings E.A., Salisbury S. Vertebral fractures in boys with Duchenne muscular dystrophy. Clin pediatrics. 42:(4):2003;353-356
44. Griggs R.C., Moxley R.T., Mendell J.R., et al. Prednisolone in Duchenne dystrophy: a randomised trial defining the time course and dose response. Arch Neurol. 48:1991;383-388
45. Dubrovksy A.L., Mesa L., Corderi J., Marco P., Flores D. Deflazacort in Duchenne dystrophy: dose-dependent effect. Neurology. 42:(suppl 3):1992;227